Biocon (BOM:532523) Construction In Progress: ₹46,833 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:532523 Biocon Ltd BOM:532523
89 GF Score
Price ₹437.00
GF Value ₹339.41
Valuation Modestly Overvalued
! 10 Warning Signs
View Full Analysis

What is Biocon Construction In Progress?

Biocon BOM:532523 -0.84% 89 Construction In Progress is ₹46,833 Mil as of Mar. 2026. GuruFocus rates BOM:532523 with a GF Score™ of 89/100 and a GF Value™ of ₹339.41 (Modestly Overvalued). The stock has 10 warning signs investors should review.

Biocon's quarterly construction in progress declined from Sep. 2025 (₹46,508 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹46,833 Mil).

Biocon's annual construction in progress increased from Mar. 2024 (₹42,156 Mil) to Mar. 2025 (₹42,954 Mil) and increased from Mar. 2025 (₹42,954 Mil) to Mar. 2026 (₹46,833 Mil).

Biocon Construction In Progress Historical Data

* Premium members only.

The historical data trend for Biocon's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocon Construction In Progress Chart

Biocon Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34,715.00 25,875.00 42,156.00 42,954.00 46,833.00

Biocon Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42,954.00 0.00 46,508.00 0.00 46,833.00
BOM:532523
89GF Score
Biocon Ltd BOM:532523
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocon Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ₹46,833 Mil mean?
Biocon (BOM:532523) has a Construction In Progress of ₹46,833 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Biocon and its competitors.
Is Biocon's Construction In Progress too high?
Biocon's current Construction In Progress is ₹46,833 Mil. Overall, Biocon has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocon's Construction In Progress compare to VRTX and REGN?
Biocon's Construction In Progress of ₹46,833 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Biocon and its competitors. Biocon's current Construction In Progress is ₹46,833 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocon stock overvalued right now?
Based on GuruFocus' analysis, Biocon (BOM:532523) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹339.41, compared to a current price of ₹437.00 — trading 28.8% above its estimated fair value. The current Construction In Progress is ₹46,833 Mil. Biocon's overall GF Score™ is 89/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Biocon (BOM:532523), the current Construction In Progress is ₹46,833 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biocon (BOM:532523) Overvalued in 2026?

Based on GuruFocus' analysis, Biocon stock appears to be overvalued. The current stock price of ₹437.00 is trading 28.8% above its estimated GF Value™ of ₹339.41. GuruFocus considers Biocon to be Modestly Overvalued.

Key valuation signals for BOM:532523:

  • Construction In Progress: ₹46,833 Mil
  • GF Value™: ₹339.41 vs. price of ₹437.00 (28.8% above fair value)
  • GF Score™: 89/100 with 10 warning signs

No single metric tells the full story. See the BOM:532523 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biocon Business Description

Other Exchanges BIOCON:India
Address 20th KM, Hosur Road, Electronics City, Bengaluru, KA, IND, 560100
Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Biosimilars which derives maximum revenue, Generics, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene. Geographically, the company generates a majority of its revenue from its customers located in India and the rest from Brazil, Singapore, and the rest of the world.
89GF Score

Get the complete analysis for BOM:532523

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹437.00
Price
₹339.41
GF Value